AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	₩21,400.00	-5.52%	1,79,496
13/26/13	₩22,650.00	-3.62%	99,052
10/26/10	₩23,500.00	+3.75%	96,892
09/26/09	₩22,650.00	-1.95%	91,720
08/26/08	₩23,100.00	-8.33%	1,28,980

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 14/07/2026			5-day change	1st Jan Change
21,400.00 ^KRW	-5.52%		-16.57%	-49.65%

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	43TCr 29Cr 25Cr 23Cr 21Cr 40Cr 2.76TCr 41Cr 276.38Cr 108.44Cr 1.35TCr 107.76Cr 105.38Cr 4.65TCr	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	39TCr 26Cr 23Cr 21Cr 20Cr 37Cr 2.51TCr 37Cr 251.83Cr 99Cr 1.23TCr 98Cr 96Cr 4.23TCr	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.52%	Yield 2024 *	-	Yield 2025	-

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW
23/04	Alligator partner Henlius presents preclinical data for HLX49	FW
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
07/04	Abclon wins 396 million won order	RE
09/03	AbClon wins 778 million won order	RE
02/03	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
01/25/01	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/25/27	Abclon wins 309 million won order	RE
20/25/20	Abclon Wins 354 Million Won Order	RE
19/25/19	AbClon Inc To Issue 1.4 Million Common Shares	RE
19/25/19	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/25/15	Abclon Wins 307 Million Won Order	RE

08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
02/03	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/24/04	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Share Price

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-5.52%
1 week	-16.57%
Current month	-23.02%
1 month	-28.19%
3 months	-57.37%
6 months	-60.52%
Current year	-49.65%

1 week	20,300	25,200
1 month	20,300	36,850
Current year	20,300	95,800
1 year	9,770	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	25/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	58	28/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	29/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	29/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	29/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	-5.52%	-16.57%	+91.07%	+30.41%	30Cr
REGENERON PHARMACEUTICALS, INC.	-1.05%	-2.97%	+14.99%	-8.68%	6.75TCr
UCB	-1.32%	-8.61%	+36.00%	+195.88%	5.11TCr
SAMSUNG BIOLOGICS CO.,LTD.	-2.29%	+36.80%	+36.80%	+36.80%	4.34TCr
CSL LIMITED	+1.34%	-1.02%	-48.96%	-53.51%	4.03TCr
BIOGEN INC.	-8.17%	-6.68%	+44.20%	-31.18%	3.09TCr
MODERNA, INC.	+0.64%	-15.46%	+105.17%	-44.43%	2.66TCr
INCYTE CORPORATION	+0.57%	-2.69%	+64.16%	+86.01%	2.28TCr
INNOVENT BIOLOGICS, INC.	+1.07%	-0.50%	+11.79%	+175.38%	1.98TCr
SWEDISH ORPHAN BIOVITRUM AB	-1.56%	-5.42%	+58.85%	+127.00%	1.65TCr
Average	-1.60%	-3.81%	+41.41%	+51.37%	3.19TCr
Weighted average by Cap.	-1.27%	-2.79%	+29.24%	+44.69%

	2024	2025
Net sales	233.98Cr 15.72L 13.74L 12.7L 11.73L 22.1L 15Cr 22.5L 1.51Cr 59.42L 7.39Cr 59.05L 57.75L 25Cr	471.41Cr 31.67L 27.68L 25.59L 23.64L 44.52L 30Cr 45.32L 3.05Cr 1.2Cr 15Cr 1.19Cr 1.16Cr 51Cr
Net income	-1.63TCr -1.1Cr -95.72L -88.48L -81.75L -1.54Cr -105.21Cr -1.57Cr -11Cr -4.14Cr -52Cr -4.11Cr -4.02Cr -177.38Cr	-1.79TCr -1.2Cr -1.05Cr -97.2L -89.8L -1.69Cr -115.57Cr -1.72Cr -12Cr -4.55Cr -57Cr -4.52Cr -4.42Cr -194.85Cr
Net Debt	-461.19Cr -30.99L -27.08L -25.03L -23.13L -43.55L -30Cr -44.34L -2.99Cr -1.17Cr -15Cr -1.16Cr -1.14Cr -50Cr	-3.79TCr -2.55Cr -2.23Cr -2.06Cr -1.9Cr -3.58Cr -244.76Cr -3.65Cr -25Cr -9.63Cr -119.85Cr -9.57Cr -9.36Cr -412.68Cr